Last reviewed · How we verify
NCT06937112
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
trial testing PET-CT examination in Lung Cancers in 20 participants. Currently enrolling.
31 January 2026
Quick facts
| Lead sponsor | Nanjing First Hospital, Nanjing Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 10 April 2025 |
| Primary completion | 31 January 2026 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- PET-CT examination
Conditions studied
- Lung Cancers — all drugs for Lung Cancers →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
- Thyroid Cancer — all drugs for Thyroid Cancer →
Sponsor
Nanjing First Hospital, Nanjing Medical University
Who can join
Adults 18 to 75, any sex, with Lung Cancers or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06937112
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET-CT examination
Trials testing the same drug.
- NCT04548037 — Assessment of Emotional Memory During Transient Global Amnesia · terminated
- NCT04065321 — Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer · recruiting
Other recruiting trials for Lung Cancers
Currently open trials in the same condition.
- NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06794125 — An Evaluation of Dose-escalation for Intrathoracic Tumours · NA · recruiting
- NCT07057648 — Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea · recruiting
- NCT06926140 — Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer · NA · recruiting
- NCT07064395 — Bright Light Therapy on Sleep Health in Lung Cancer Patients · NA · recruiting
Other Nanjing First Hospital, Nanjing Medical University trials
Trials by the same sponsor.
- NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
- NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
- NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
- NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
- NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06937112 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
- Last refreshed: 22 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06937112.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing